Search results
Showing 901 to 915 of 1215 results for pain
NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .
monitoring of temperature and level of consciousness (AVPU [alert, voice, pain, unresponsive]), and 4‑hourly monitoring of respiratory...
Brain tumours (primary) and brain metastases in over 16s (QS203)
This quality standard covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in adults (aged 16 or over). It describes high-quality care in priority areas for improvement.
View quality statements for QS203Show all sections
Sections for QS203
- Quality statements
- Quality statement 1: GP direct access to MRI
- Quality statement 2: Named healthcare professional
- Quality statement 3: 5-aminolevulinic acid-guided resection
- Quality statement 4: Risk of late effects of treatment
- Quality statement 5: Neurological rehabilitation
- About this quality standard
Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.
Bortezomib for previously untreated mantle cell lymphoma (TA370)
Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.
Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.
Read the biographies of our medical technologies advisory committee members.
Read the biographies of our medical technologies advisory committee members.
Transperineal biopsy for diagnosing prostate cancer (HTG680)
Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer.
Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal.
Discontinued Reference number: GID-TAG402
NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.